Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Moss Adams Wealth Advisors LLC

Moss Adams Wealth Advisors LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 212.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,357 shares of the biopharmaceutical company’s stock after purchasing an additional 923 shares during the period. Moss Adams Wealth Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $967,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Monarch Capital Management Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 106.0% during the fourth quarter. Monarch Capital Management Inc. now owns 1,067 shares of the biopharmaceutical company’s stock valued at $760,000 after purchasing an additional 549 shares during the period. HB Wealth Management LLC grew its position in Regeneron Pharmaceuticals by 8.2% in the 4th quarter. HB Wealth Management LLC now owns 2,129 shares of the biopharmaceutical company’s stock valued at $1,516,000 after buying an additional 161 shares in the last quarter. Trust Co. of Vermont increased its stake in Regeneron Pharmaceuticals by 199.4% during the 4th quarter. Trust Co. of Vermont now owns 470 shares of the biopharmaceutical company’s stock valued at $335,000 after buying an additional 313 shares during the period. Integrated Investment Consultants LLC raised its position in shares of Regeneron Pharmaceuticals by 6.8% during the 4th quarter. Integrated Investment Consultants LLC now owns 609 shares of the biopharmaceutical company’s stock worth $434,000 after buying an additional 39 shares in the last quarter. Finally, B & T Capital Management DBA Alpha Capital Management lifted its stake in shares of Regeneron Pharmaceuticals by 154.8% in the 4th quarter. B & T Capital Management DBA Alpha Capital Management now owns 3,147 shares of the biopharmaceutical company’s stock worth $2,242,000 after acquiring an additional 1,912 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on REGN shares. Piper Sandler lowered their price objective on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. UBS Group downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $1,130.00 to $738.00 in a research note on Thursday. Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price objective for the company. Wells Fargo & Company lowered their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. Finally, Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,015.38.

Regeneron Pharmaceuticals Price Performance

REGN opened at $681.58 on Friday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $666.25 and a 12-month high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $74.90 billion, a P/E ratio of 16.87, a PEG ratio of 1.60 and a beta of 0.10. The stock has a fifty day moving average of $738.60 and a 200-day moving average of $949.99.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.